Total Payments
$126,404
2024 Payments
$30,581
Companies
19
Transactions
165
Medicare Patients
94
Medicare Billing
$13,222
Payment Breakdown by Category
Consulting$95,916 (75.9%)
Travel$18,706 (14.8%)
Food & Beverage$4,771 (3.8%)
Other$4,530 (3.6%)
Research$2,478 (2.0%)
Education$3.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $95,916 | 25 | 75.9% |
| Travel and Lodging | $18,706 | 48 | 14.8% |
| Food and Beverage | $4,771 | 70 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,530 | 2 | 3.6% |
| Unspecified | $2,478 | 19 | 2.0% |
| Education | $3.75 | 1 | 0.0% |
Payments by Type
General
$123,926
146 transactions
Research
$2,478
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $42,316 | 51 | $0 (2024) |
| GENZYME CORPORATION | $23,985 | 19 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $14,425 | 4 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $9,273 | 14 | $0 (2024) |
| Genentech USA, Inc. | $6,175 | 7 | $0 (2024) |
| AstraZeneca UK Limited | $5,861 | 12 | $0 (2022) |
| Pulmonx Corporation | $5,290 | 8 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $4,694 | 11 | $0 (2024) |
| Circassia Pharmaceuticals Inc | $4,374 | 9 | $0 (2017) |
| PneumRx, Inc | $4,166 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,581 | 25 | GlaxoSmithKline, LLC. ($8,826) |
| 2023 | $32,862 | 31 | GENZYME CORPORATION ($11,955) |
| 2022 | $10,612 | 18 | GENZYME CORPORATION ($5,441) |
| 2019 | $9,819 | 24 | GlaxoSmithKline, LLC. ($8,313) |
| 2018 | $9,307 | 24 | AstraZeneca UK Limited ($4,672) |
| 2017 | $33,224 | 43 | Boehringer Ingelheim Pharma GmbH & Co.KG ($14,425) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 10/02/2024 | Pulmonx Corporation | ZEPHYR ENDOBRONCHIAL VALVE (Device) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: PULMONOLOGY | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $51.21 | General |
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $88.20 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $762.66 | General |
| 08/16/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $292.67 | General |
| 08/16/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $284.28 | General |
| 08/13/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: PULMONOLOGY | ||||||
| 07/19/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,525.00 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,115.00 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $415.45 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $385.03 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Travel and Lodging | In-kind items and services | $228.23 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $12.74 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $11.50 | General |
| 06/22/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $7.46 | General |
| 05/28/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $7.06 | General |
| Category: PULMONOLOGY | ||||||
| 05/21/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $45.79 | General |
| Category: PULMONOLOGY | ||||||
| 03/19/2024 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $29.73 | General |
| Category: PULMONOLOGY | ||||||
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $40.00 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $38.10 | General |
| 01/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $37.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,506 | 15 |
| A randomized, double blind, Sponsor open, placebo controlled, 52 week study evaluating the effect of danirixin GSK1325756 on lung function and health related quality of life in participants with mild to moderate Chronic Obstructive Pulmonary Disease CO | GlaxoSmithKline, LLC. | $972.40 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 19 | 22 | $4,272 | $1,247 |
| 2022 | 1 | 20 | 38 | $7,484 | $2,948 |
| 2021 | 2 | 41 | 76 | $18,789 | $6,173 |
| 2020 | 1 | 14 | 34 | $8,806 | $2,853 |
Total Patients
94
Total Services
170
Medicare Billing
$13,222
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 22 | $4,272 | $1,247 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 38 | $7,484 | $2,948 | 39.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 28 | 61 | $15,799 | $4,982 | 31.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 13 | 15 | $2,990 | $1,191 | 39.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 34 | $8,806 | $2,853 | 32.4% |
About Frank Sciurba
Frank Sciurba is a Specialist healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285609545.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Frank Sciurba has received a total of $126,404 in payments from pharmaceutical and medical device companies, with $30,581 received in 2024. These payments were reported across 165 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($95,916).
As a Medicare-enrolled provider, Sciurba has provided services to 94 Medicare beneficiaries, totaling 170 services with total Medicare billing of $13,222. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Pittsburgh, PA
- Active Since 02/21/2006
- Last Updated 03/25/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1285609545
Products in Payments
- STIOLTO RESPIMAT (Drug) $14,425
- DUPIXENT (Biological) $9,736
- NUCALA (Biological) $8,125
- ZEPHYR ENDOBRONCHIAL VALVE (Device) $5,091
- FASENRA (Drug) $4,672
- TUDORZA PRESSAIR (Drug) $4,244
- PNEUMRX COILS (Device) $4,239
- AIRSUPRA (Drug) $1,928
- DUPIXENT (Drug) $1,506
- SPIRIVA (Drug) $1,500
- TRELEGY ELLIPTA (Drug) $435.03
- ANORO (Drug) $425.75
- ALIYA SYSTEM (Device) $249.00
- CHARTIS CATHETER (Device) $199.18
- NIOX VERO DEVICE (Device) $130.44
- Perforomist (Drug) $101.73
- BEADS - BIO (Device) $65.54
- Spiration Valve System (Device) $14.43
- FASENRA (Biological) $7.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Pittsburgh
Dr. Lawrence Crossett, Md, MD
Specialist — Payments: $5.3M
Specialist $5.3M
Dr. James Bradley, Md, MD
Specialist — Payments: $5.0M
Specialist $5.0M
Darrell Triulzi
Specialist — Payments: $3.3M
Specialist $3.3M
Dr. Mark Yazer, Md, MD
Specialist — Payments: $2.4M
Specialist $2.4M
Lirong Qu
Specialist — Payments: $2.4M
Specialist $2.4M
Dr. Miguel Regueiro, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M